Drug Profile
Nitric oxide - Beyond Air
Alternative Names: AIT-BRO; AIT-CF; AIT-COPD; AIT-NTM; AIT-NV; AIT-RSV; AIT-WH; gaseous NO - Beyond Air; gNO - Beyond Air; iNO - Beyond Air™; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN; Ultra-High Concentration Nitric Oxide Therapy - Beyond Cancer; UNO therapy - Beyond CancerLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer Beyond Air; Schneider Childrens Medical Center of Israel; University of British Columbia
- Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bronchitis
- Phase II Chronic obstructive pulmonary disease; COVID-19 pneumonia; Cystic fibrosis; Diabetic foot ulcer; Mycobacterial infections; Stroke
- Phase I Solid tumours
- No development reported COVID 2019 infections; Respiratory tract infections
- Discontinued Asthma; Pneumonia
Most Recent Events
- 12 Feb 2024 Beyond Air terminates phase I trial in Chronic obstructive pulmonary disease (Inhalation) prior to initiation
- 28 Jan 2024 No recent reports of development identified for phase-I development in Mycobacterial-infections in Australia (Inhalation)
- 07 Nov 2023 Adverse events data from a phase I trial in Solid tumours released by Beyond Cancer